Welcome to our dedicated page for West Bancorporation SEC filings (Ticker: WTBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for loan-loss details, deposit growth, or trust fee trends inside West Bancorporation Inc’s disclosures? Investors typically dive into the company’s 10-K and 10-Q to gauge credit quality and net interest margin, yet those documents run well past 150 pages. Stock Titan’s AI-powered summaries present West Bancorporation Inc SEC filings explained simply, so you can locate provisioning numbers, segment data, and regional lending exposures in minutes instead of hours.
Use the left-hand filters to jump straight to the filing you need. The West Bancorporation Inc quarterly earnings report 10-Q filing reveals margin swings and community loan growth; our platform flags them automatically. Every Form 8-K material event—branch openings, dividend announcements, even sudden credit downgrades—is indexed here with West Bancorporation Inc 8-K material events explained. Curious about executive sentiment? West Bancorporation Inc insider trading Form 4 transactions hit this page in real time, coupled with AI that highlights buying versus selling trends, so you never miss a potential signal.
Whether you’re monitoring capital ratios, parsing the West Bancorporation Inc proxy statement executive compensation, or comparing revenue lines across periods, our coverage spans every form:
- West Bancorporation Inc annual report 10-K simplified
- West Bancorporation Inc earnings report filing analysis
- West Bancorporation Inc Form 4 insider transactions real-time
Amneal Pharmaceuticals (AMRX) filed an 8-K disclosing a major refinancing package. On 24 Jul 2025 the company priced $600 million of 6.875% senior secured notes due 2032 at par in a Rule 144A/Reg S private placement. The note size was reduced from the previously announced $750 million.
Concurrently, subsidiary Amneal Pharmaceuticals LLC plans to enter a new $2.1 billion, seven-year term loan B facility, upsized by $300 million from prior guidance. Together, proceeds from the notes and the new term B loans will be used to refinance existing term B loans and fully repay amounts outstanding under the ABL facility, along with related fees and expenses. The note offering is not contingent upon closing of the new term loan; both transactions are expected to close 1 Aug 2025, subject to customary conditions.
The securities will not be registered under the Securities Act and are being offered only to qualified institutional buyers (Rule 144A) and non-U.S. persons (Reg S).
West Bancorporation (WTBA) delivered a solid Q2 2025. Net income climbed to $7.98 million or $0.47 per share, a 54 % YoY surge as net interest income expanded 24 % to $21.4 million. The lift stemmed from a $3.8 million drop in interest expense while interest income held steady. Modest growth in non-interest revenue (+3 %) and tight cost control (+2 % expenses) pushed pre-tax income to $10.3 million (+62 %).
For the six-month period, earnings rose to $15.8 million ($0.94 EPS) from $11.0 million. Deposits increased $34.4 million to $3.39 billion, offsetting a $38.6 million contraction in the loan book to $2.97 billion. Cash and equivalents swelled to $345 million (+42 % YTD), boosting liquidity.
Credit metrics remain pristine: no non-accrual loans, no charge-offs and a stable $30.5 million ACL; credit-loss provision was zero. Equity improved to $240.9 million on stronger earnings and a $5.5 million recovery in AOCI, though unrealised AFS losses still total $83.8 million. The quarterly dividend was maintained at $0.25 per share.